Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$3.25 USD

3.25
340,641

+0.03 (0.93%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $3.26 +0.01 (0.31%) 7:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Puma Biotech (PBYI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Celcuity (CELC) Soars on Agreement With Pfizer & Study Data

by Zacks Equity Research

Celcuity (CELC) is developing gedatolisib in combination with Pfizer's Ibrance and an endocrine therapy in breast cancer patients. It inks deal to gain exclusive rights to gedatolisib from Pfizer.

Zacks Equity Research

Puma Biotech (PBYI) Down 6.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall

by Zacks Equity Research

Puma Biotech (PBYI) reports wider-than-expected fourth-quarter loss while sales beat estimates.

Zacks Equity Research

Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Roche's (RHHBY) Phesgo Gets EU Nod to Treat Breast Cancer

by Zacks Equity Research

Roche's (RHHBY) fixed-dose combination of Perjeta and Herceptin administered subcutaneously gets approved by the EC for the treatment of early and metastatic HER2-positive breast cancer.

Zacks Equity Research

Why Is Puma Biotech (PBYI) Up 36% Since Last Earnings Report?

by Zacks Equity Research

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut

by Zacks Equity Research

Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.

Zacks Equity Research

Puma Biotech (PBYI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of -139.39% and -4.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Is Puma Biotech (PBYI) Down 7.2% Since Last Earnings Report?

by Zacks Equity Research

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Puma's (PBYI) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

Puma Biotech's (PBYI) bottom and the top line better estimates for the second quarter of 2020.

Zacks Equity Research

Puma Biotech (PBYI) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 130.77% and 26.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Roche's SC Formulation of Perjeta-Herceptin Combo Gets FDA Nod

by Zacks Equity Research

Roche (RHHBY) receives FDA approval for a fixed-dose combination of Perjeta and Herceptin, Phesgo, plus chemotherapy as a treatment for HER2-positive breast cancer.

Nilanjan Choudhury headshot

Why the Sell-Off in These 5 Stocks is a Buying Opportunity

by Nilanjan Choudhury

We have zeroed in on five stocks that have witnessed a slump this past week but have a favorable Zacks Rank #1 (Strong Buy) or 2 (Buy).

Zacks Equity Research

Puma Biotech (PBYI) Up 7.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Moving Average Crossover Alert: Puma Biotechnology

by Zacks Equity Research

Puma Biotechnology, Inc. (PBYI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Equity Research

Puma Biotechnology, Inc. (PBYI) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Puma Biotechnology, Inc. (PBYI).

Tirthankar Chakraborty headshot

New Strong Buy Stocks for May 13th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Zacks Equity Research

Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Puma Biotech's (PBYI) loss and revenues better estimates in the first quarter of 2020.

Zacks Equity Research

Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 45.57% and 16.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to Decline

by Zacks Equity Research

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Puma Biotech (PBYI) Down 44% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Puma Biotech's (PBYI) Nerlynx Aids Growth Despite Competition

by Zacks Equity Research

Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. High dependence on Nerlynx for growth remains a woe.